Drug Profile
Stroke stem cell therapy - Histocell
Latest Information Update: 15 Feb 2022
Price :
$50
*
At a glance
- Originator Histocell
- Developer Histocell; University Hospital Grenoble
- Class Antihyperglycaemics; Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements; Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 15 Feb 2022 Discontinued - Phase-II for Stroke in United Kingdom, Spain, France, Finland, Czech Republic (IV) (Histocell pipeline, February 2022)
- 01 Sep 2015 Phase-II clinical trials in Stroke in United Kingdom, Spain, France, Finland, Czech Republic (IV) (Histocell pipeline, September 2015)